Simon Lord
University of Oxford
CancerInternal medicineEndocrinologyOncologyTranscriptomeAdverse effectIn vivoChemotherapyCapecitabineHypoxia (medical)Triple-negative breast cancerMetforminAngiogenesisOxaliplatinPopulationIn patientLipid metabolismCancer researchBreast cancerClinical trialMedicineBiologyGastroenterologyCancer cell
53Publications
11H-index
807Citations
Publications 51
Newest
#1Geoffrey I. Shapiro (Harvard University)H-Index: 103
#2Robert Wesolowski (OSU: Ohio State University)H-Index: 18
Last. Timothy A. Yap (ICR: Institute of Cancer Research)H-Index: 24
view all 14 authors...
BACKGROUND Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. We assessed the safety, tolerability, pharmacokinetics, and preliminary efficacy of berzosertib plus cisplatin. METHODS Adult patients with advanced solid tumours refractory or resistant to standard of care therapies received ascending doses of cisplatin (day 1) and berzosertib (days 2 and 9) every 3 weeks (Q3W). RESULTS T...
Source
#5Wei-Pang Chung (NCKU: National Cheng Kung University)H-Index: 1
Source
#1Peter Hall (Edin.: University of Edinburgh)H-Index: 145
#2Daniel Swinson (National Health Service)
view all 89 authors...
Importance Older and/or frail patients are underrepresented in landmark cancer trials. Tailored research is needed to address this evidence gap. Objective The GO2 randomized clinical trial sought to optimize chemotherapy dosing in older and/or frail patients with advanced gastroesophageal cancer, and explored baseline geriatric assessment (GA) as a tool for treatment decision-making. Design, Setting, and Participants This multicenter, noninferiority, open-label randomized trial took place at onc...
Source
#1Richard D. Baird (University of Cambridge)H-Index: 24
#2Constanza Linossi (University of Cambridge)H-Index: 2
Last. Aurelius Omlin (HSG: University of St. Gallen)H-Index: 34
view all 15 authors...
PURPOSEA first-in-human study was performed with MP0250, a DARPin drug candidate. MP0250 specifically inhibits both vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) with...
2 CitationsSource
#1Shivan SivakumarH-Index: 8
Last. Christopher YauH-Index: 28
view all 19 authors...
Source
#1Sarat ChandarlapatyH-Index: 51
#2Aditya BardiaH-Index: 52
Last. Mario CamponeH-Index: 79
view all 16 authors...
Source
#1Matteo Di Giovannantonio (University of Oxford)H-Index: 1
#2Benjamin Howell Lole Harris (University of Oxford)H-Index: 4
Last. Gareth L. BondH-Index: 25
view all 14 authors...
BACKGROUND Height and other anthropometric measures are consistently found to associate with differential cancer risk. However, both genetic and mechanistic insights into these epidemiological associations are notably lacking. Conversely, inherited genetic variants in tumour suppressors and oncogenes increase cancer risk, but little is known about their influence on anthropometric traits. METHODS By integrating inherited and somatic cancer genetic data from the Genome-Wide Association Study Cata...
Source
#1Simon Lord (University of Oxford)H-Index: 11
#2Jennifer Collins (University of Oxford)H-Index: 6
Last. Adrian L. Harris (University of Oxford)H-Index: 191
view all 21 authors...
Background: Epidemiological studies suggest that metformin may reduce the incidence of cancer in patients with diabetes and multiple late phase clinical trials assessing the potential of repurposing this drug are underway. Transcriptomic profiling of tumour samples is an excellent tool to understand drug bioactivity, identify candidate biomarkers and assess for mechanisms of resistance to therapy. Methods: 36 patients with untreated primary breast cancer were recruited to a window study and tran...
6 CitationsSource
#1Francesca Aroldi (University of Oxford)H-Index: 7
#2Simon Lord (University of Oxford)H-Index: 11
Window of opportunity trials exploit the ‘window’ of time after cancer diagnosis, typically prior to initiation of cancer therapy. In recent years this study design has become a more regular feature of drug development, as this ‘window’ provides an opportunity to carry out a thorough pharmacodynamic assessment of a therapy of interest in tumours that are unperturbed by prior treatment. Many of the first window trials interrogated the bioactivity of drugs being repurposed for cancer treatment, in...
2 CitationsSource
#1Anne Thomas (University of Leicester)H-Index: 12
#1Anne L. Thomas (University of Leicester)H-Index: 32
Last. Mark R. Middleton (University of Oxford)H-Index: 64
view all 13 authors...
Abstract Background AZD8931 has equipotent activity against epidermal growth factor receptor, erbB2, and erbB3. Primary objectives were to determine the recommended phase II dose (RP2D) of AZD8931 + chemotherapy, and subsequently assess safety/preliminary clinical activity in patients with operable oesophagogastric cancer (OGC). Methods AZD8931 (20 mg, 40 mg or 60 mg bd) was given with Xelox (oxaliplatin + capecitabine) for eight 21-day cycles, continuously or with intermittent schedule (4 days ...
1 CitationsSource